GLOFITAMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 00:05:25 GMT 2025` Edited by `admin` on `Wed Apr 02 00:05:25 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	06P3KLK2J8
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

GLOFITAMAB

Official Name

English

RG-6026

Preferred Name

English

IMMUNOGLOBULIN G1 (149-GLUTAMIC ACID,215-GLUTAMIC ACID,461-ALANINE,462-ALANINE,556-GLYCINE,581-CYSTEINE,593-TRYPTOPHAN), ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 VH-CH1 FRAGMENT) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 10-AMINO ACID

Common Name

English

glofitamab [INN]

Common Name

English

GLOFITAMAB [USAN]

Common Name

English

ANTI-CD20/CD3 BISPECIFIC MONOCLONAL ANTIBODY RO7082859

Common Name

English

RO7082859

Code

English

RO-7082859

Code

English

IMMUNOGLOBULIN G1-LAMBDA/KAPPA WITH DOMAIN CROSS-OVER, ANTI-(HOMO SAPIENS MS4A1 (MEMBRANE-SPANNING 4-DOMAINS SUBFAMILY A MEMBER 1, CD20)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)) MONOCLONAL ANTIBODY, BISPECIFIC, TRIVALENTGAMMA-LAMBDA HEAVY CHAIN

Common Name

English

Glofitamab [WHO-DD]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

864121

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

Code System Code Type Description

DAILYMED

06P3KLK2J8

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

PRIMARY

SMS_ID

100000182956

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

PRIMARY

USAN

HI-119

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

PRIMARY

INN

11145

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

PRIMARY

CAS

2229047-91-8

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

PRIMARY

FDA UNII

06P3KLK2J8

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

PRIMARY

NCI_THESAURUS

C148486

Created by admin on Wed Apr 02 00:05:25 GMT 2025 , Edited by admin on Wed Apr 02 00:05:25 GMT 2025

PRIMARY

From	To
1_22	1_96
1_146	1_202
1_255	1_323
1_371	1_427
1_447	5_232
1_453	2_228
1_456	2_231
1_488	1_548
1_222	3_219
1_594	1_652
2_22	2_96
2_146	2_202
2_222	4_219
2_263	2_323
2_369	2_427
1_581	2_351
3_23	3_93
3_139	3_199
4_23	4_93
4_139	4_199
5_22	5_98
5_152	5_212

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_524
N	2_299

Related Record Type Details


					TB2Q79LBS0

B-LYMPHOCYTE ANTIGEN CD20

TARGET->LIGAND

Amount:


					1U72JD9DDZ

T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN

TARGET -> ACTIVATOR

Glofitamab-GXBM

SUB_CONCEPT->SUBSTANCE

Amount:

Related Record Type Details


					06P3KLK2J8

ACTIVE MOIETY

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42
AMINO ACID REMOVAL	[1_674] [2_449]	C-TERMINUS			LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL